SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Trevena, Inc. Presents Phase 1 Clinical Data for TRV027, a ß-arrestin Biased AT1R Ligand, at the 2012 Heart Failure Society of America Meeting